Strong Q2 Drives Axogen to Raise 2026 Revenue Guidance to at Least 24% Growth
AXGN has more than doubled off its 52-week low of $12.385.
Summary
Axogen posted Q2 2026 revenue of $69.7M (+23.1% YoY) and raised its full-year revenue guidance to at least 24% growth, or $279M. Adjusted EBITDA came in at $8.4M, and the company delivered positive free cash flow while maintaining a debt-free balance sheet.
Key Events · Earnings and Guidance · AXGN
-
Q2 Revenue Beats, Guidance Raised
Broad-based strength across Extremities, OMF/H&N, and Breast drove revenue to $69.7M, a 23.1% year-over-year gain. Full-year 2026 revenue guidance was raised to at least 24% growth, or $279M.
-
Adjusted Profitability Solid
Despite a slight gross margin decline to 72.7%, operating leverage pushed adjusted EBITDA to $8.4M (12.1% margin) and adjusted net income to $7.3M, or $0.12 per share.
-
Cash Generation and Debt-Free Balance Sheet
Cash and investments climbed $9.8M sequentially to $113.4M. Free cash flow reached $4.1M in the first half of 2026, and the company carries no debt after extinguishing prior obligations.
-
Commercial Momentum Across Markets
Breast revenue surged more than 50% year-over-year, while Extremities held steady and OMF/H&N saw continued adoption. The company added over 130 active surgeons year-to-date and expanded its sales force.
Analysis · AXGN · Industrial Applications And Services
Second-quarter revenue reached $69.7 million, a 23.1% year-over-year increase, prompting management to lift the full-year 2026 revenue outlook to at least 24% growth, or $279 million. Gross margin edged down to 72.7% on product mix, yet adjusted EBITDA held firm at $8.4 million. The first half generated $4.1 million in positive free cash flow, and the quarter closed with $113.4 million in cash and no debt. The raised guidance and improving cash generation underscore growing commercial traction for the nerve repair portfolio across target markets, though the stock's reaction will hinge on whether the updated outlook satisfies elevated expectations.
At the time of this filing, AXGN was trading at $40.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $12.39 to $46.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.